Eating less usually means getting fewer nutrientsand your hair follicle is a small but demanding micro-organ that feels it
In this guide, well compare Retatrutide and Tirzepatide from a research perspectiveincluding how theyre designed, why scientists are studying them, and where each fits into todays peptide research landscape
[DOI] [PubMed] [Google Scholar] 151.Sun L., Goh H.J., Govindharajulu P., Leow M.K., Henry C.J
Compared with db/db mice, the Low and High groups treated with berberine had lower blood glucose levels after intraperitoneal injection of glucose and insulin (Figures 1E, G)
Whereas general obesity and central adiposity, in particular, are the primary factors responsible for the development of insulin resistance, postprandial increases in insulin secretion causes a further expansion of the adipose tissue mass, which further worsens insulin resistance
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
